Literature DB >> 17214794

Should the extent of lobular neoplasia on core biopsy influence the decision for excision?

Lisa E Esserman1, Ladan Lamea, Silvio Tanev, Robert Poppiti.   

Abstract

The purpose of this study was to determine whether there is a criterion that can be utilized to determine if excisional biopsy is indicated following the diagnosis of lobular neoplasia (LN) on core biopsy. Retrospective review of patient records with diagnosis of LN as highest risk diagnosis on core biopsy was performed. LN was defined to include both atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) and was categorized as focal or diffuse. The pathology was correlated with the mammographic finding to determine whether the diagnosis of LN was incidental or related to the mammographic finding. For those patients who did not undergo excision, follow-up data are presented along with treatment information. A total of 4,555 breast core biopsies were performed at our institution from January 1997 through March 2005. Of these, 35 patients were diagnosed with LN. Twenty six (74%) went on to excision and nine (26%) were followed. Biopsy was recommended for mammographically detected calcifications in the majority of cases. Twenty four (92%) of the 26 excised cases had focal LN and 2 of 26 (8%) had diffuse LN. Infiltrating lobular carcinoma was diagnosed in both cases of diffuse LN and no infiltrating carcinoma was seen when focal LN was diagnosed on core. Excision may not be necessary when a diagnosis of only focal LN is made on core biopsy. Diffuse LN may indicate an associated invasive cancer and should prompt excision.

Entities:  

Mesh:

Year:  2007        PMID: 17214794     DOI: 10.1111/j.1524-4741.2006.00363.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  8 in total

1.  Surgical implications and variability in the use of the flat epithelial atypia diagnosis on breast biopsy specimens.

Authors:  Laura S Samples; Mara H Rendi; Paul D Frederick; Kimberly H Allison; Heidi D Nelson; Thomas R Morgan; Donald L Weaver; Joann G Elmore
Journal:  Breast       Date:  2017-05-03       Impact factor: 4.380

2.  Management of high-risk breast lesions diagnosed on core biopsies and experiences from prospective high-risk breast lesion conferences at an academic institution.

Authors:  Xiaoxian Li; Zhongliang Ma; Toncred M Styblo; Cletus A Arciero; Haibo Wang; Michael A Cohen
Journal:  Breast Cancer Res Treat       Date:  2020-10-17       Impact factor: 4.872

3.  Pleomorphic Lobular Carcinoma In Situ: Radiologic-Pathologic Features and Clinical Management.

Authors:  Meghan R Flanagan; Mara H Rendi; Kristine E Calhoun; Benjamin O Anderson; Sara H Javid
Journal:  Ann Surg Oncol       Date:  2015-04-17       Impact factor: 5.344

4.  Risk of Lobular Neoplasia Upgrade with Synchronous Carcinoma.

Authors:  Isabelle L Crary; Elizabeth U Parker; Kathryn P Lowry; Pranav P Patwardhan; Thing Rinda Soong; Sara H Javid; Kristine E Calhoun; Meghan R Flanagan
Journal:  Ann Surg Oncol       Date:  2022-07-08       Impact factor: 4.339

5.  Treatment and survival outcomes of lobular carcinoma in situ of the breast: a SEER population based study.

Authors:  Pu Cheng; Qi Huang; Jiafeng Shou; Guoming Hu; Mengjiao Han; Jian Huang
Journal:  Oncotarget       Date:  2017-10-03

6.  Lobular carcinoma in situ of the breast - correlation between minimally invasive biopsy and final pathology.

Authors:  Bartłomiej Szynglarewicz; Piotr Kasprzak; Agnieszka Hałoń; Rafał Matkowski
Journal:  Arch Med Sci       Date:  2016-10-26       Impact factor: 3.318

7.  Lesions of "uncertain malignant potential" in the breast (B3) identified with mammography screening.

Authors:  Christiane Richter-Ehrenstein; Katharina Maak; Sonja Röger; Tilman Ehrenstein
Journal:  BMC Cancer       Date:  2018-08-16       Impact factor: 4.430

8.  The significance of lobular neoplasia on needle core biopsy of the breast.

Authors:  S Menon; G J R Porter; A J Evans; I O Ellis; C W Elston; Z Hodi; A H S Lee
Journal:  Virchows Arch       Date:  2008-05       Impact factor: 4.064

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.